To identify risk factors for pneumococcal infection among human immunodeficiency virusinfected patients, a nested case-control study was done in an urban university human immunodeficiency virus clinic. Subjects with pneumococcal illness seen between 1 January 1990 and 1 July 1994 (n = 85) were randomly matched to controls from the same population. Patients with pneumococcal disease were more likely than controls to be African American (adjusted odds ratio [ 
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To identify risk factors for pneumococcal infection among human immunodeficiency virusinfected patients, a nested case-control study was done in an urban university human immunodeficiency virus clinic. Subjects with pneumococcal illness seen between 1 January 1990 and 1 July 1994 (n = 85) were randomly matched to controls from the same population. Patients with pneumococcal disease were more likely than controls to be African American (adjusted odds ratio [ (adjusted OR = 0.38) and pneumococcal vaccination when the subject had >200 CD4 cells/mm 3 (adjusted OR = 0.22) were less common in cases than in controls. Similar results were found when only cases with infections of usually sterile sites were analyzed. Pneumococcal vaccine may be most protective when it is administered before advanced immunodeficiency develops.
Streptococcus pneumoniae is a common bacterial respiratory pathogen in persons with human immunodeficiency virus (HIV) infection. The incidence of pneumococcal bacteremia in patients with AIDS in San Francisco was 9.4/1000 person-years, compared with 0.07/1000 person years in a non-HIV-infected population of similar age [1, 2] . In addition, HIV-infected patients have a higher rate of recurrence of pneumococcal infection than HIV-seronegative patients [1, [3] [4] [5] [6] . Mortality from pneumococcal disease in HIV-infected persons is substantial (5%-20%) [7] . Consequently, prevention of pneumococcal disease in subjects with HIV infection is an important clinical objective. Risk factors for bacterial respiratory infection in HIV-infected patients include advanced immunodeficiency, injection drug use, cigarette and drug smoking, and neutropenia [8] [9] [10] . While predisposing factors for pneumococcal disease are well known for general populations [11] , specific risk factors for pneumococcal infections in HIV-infected persons have not been described.
Although the American College of Physicians and the Advisory Committee on Immunization Practices (ACIP) recommend that all persons with HIV infection~2 years old receive the pneumococcal polysaccharide vaccine [12, 13] , vaccine efficacy in HIV-infected subjects has not been demonstrated, and failures have been reported [14] [15] [16] . The use oftrimethoprimsulfamethoxazole [17, 18] to prevent Pneumocystis carinii pneumonia may reduce the incidence of serious bacterial infections in HIV-infected patients, but the efficacy of chemoprophylaxis for pneumococcal disease has not been established [6] .
To assess the effectiveness of the pneumococcal vaccine and prophylactic antibiotic therapy and to delineate the factors that modify the risk for S. pneumoniae infection among HIV-infected patients, we conducted a nested case-control study among a cohort of patients from a large, urban HIV clinic.
Methods
Case-patients (cases) and controls for this study were selected from a demographically heterogeneous cohort of adults with HIV infection who presented for initial evaluation and care at the Johns Hopkins Hospital HIV Clinic between 1 January 1989 and 1 June 1994 [19, 20] . All subjects had a comprehensive baseline assessment that included collection of detailed demographic and clinical data. A list of all culture specimens growing S. pneumoniae in the Johns Hopkins Hospital Clinical Microbiology Laboratory between 1 January 1990 and 1 July 1994 was used to identify potential cases from the cohort. Cases were defined as patients in the cohort with an acute febrile illness and a culture positive for S. pneumoniae recovered from blood or another sterile site or a positive culture from a nonsterile site (e.g., respiratory secretions) and the presence of at least three clinical symptoms and three signs. Confirmatory clinical symptoms included fever, chills, sweats, cough, sputum production, chest pain, shortness of breath, headache, or change in mental status. Confirmatory signs included temperature >37.8°C, heart rate > 100/min, respiratory rate >24 breaths/min, orthostatic blood pressure or pulse, cyanosis, and con-solidation on lung examination or a chest radiograph showing lobar or segmental infiltrates.
One control was selected randomly from the same cohort using a computer-generated algorithm. Controls were matched to cases by calendar time of clinic enrollment (within 6 months) and by duration of follow-up. For cases, duration of follow-up was defined as the time from first presentation to the clinic to the time of positive pneumococcal culture (index time). For controls, duration of follow-up was the time from presentation to the index time of the matched case. On detailed record review, controls could have no history of pneumococcal disease. Subjects with a history of probable bacterial respiratory infections (but no cultures) were excluded from serving as controls.
Pneumococcal vaccination was defined as written documentation of vaccine administration~2 weeks before the onset of symptoms in cases or by the end of follow-up in controls. A 2-week interval was selected because of the time required after vaccination for an antibody response to develop. This period is consistent with the definition used in randomized clinical trials of pneumococcal vaccine efficacy [21, 22] . We routinely record a history ofpneumococcal vaccination in the standard baseline assessment of all patients enrolled in the clinic and note vaccinations done in the clinic. In all subjects with a history of vaccination, we required corroborating records to document vaccine receipt. We analyzed the association of pneumococcal vaccine stratified by the level of CD4 cell count (e.g., >200 or~200 cells/mm 3 ) at the time (:±:90 days) of vaccination.
Demographic data (age, race, sex), HIV risk behavior, and clinical, laboratory, and medication data were abstracted from the patients' hospital and ambulatory records. We defined injection drug use if, at the initial assessment, a patient reported using drugs intravenously. Clinical assessment (stage of HIV disease [i.e., asymptomatic, symptomatic, or AIDS], prior opportunistic illnesses) was made at baseline and at the index time for cases and controls. AIDS was defined by the 1993 CDC surveillance case definition [23] . Laboratory values were obtained at first presentation and at the index time (value measured nearest to index time but within 6 months): These included CD4 lymphocyte and white blood cell counts and hematocrit, creatinine, and albumin values. Laboratory data were not available within 6 months of the index time for 4 cases and 1 control. For these subjects, we used the laboratory value nearest the index time. Use of zidovudine and trimethoprim-sulfamethoxazole was determined by chart review. Use of medication was defined as receipt during the 30 days before the index time.
For this nested case-control study, McNemar's test was used to calculate the X 2 and associated P values for the comparison of dichotomous variables in cases and controls [24] . The odds ratio (OR) with approximate 95% confidence intervals and 2-tailed P values were calculated using standard formulas [24] . A paired t test was used to compare laboratory values recorded as continuous variables. Conditional multivariate logistic regression was used to estimate the adjusted OR for variables associated with pneumococcal infection [25] . Variables analyzed included those associated with infection in the bivariate analyses. Due to the small sample size and the need to retain as much data as possible, mean values were used in the logistic regression if the value of a variable was missing. No variable in the model had> 10% missing data.
Results
Between January 1990 and June 1994, 89 HIV-seropositive patients from the clinic had cultures that yielded S. pneumoniae. Of these, 87 met the criteria for cases, and 85 were studied: 1 patient could not be matched to a control, and I record lacked sufficient information for complete evaluation. One control was matched to each of the 85 cases. Of the 85 patients enrolled as cases, S. pneumoniae was isolated from respiratory specimens only of 49 patients, from blood only of 24 patients, from other usually sterile sites in 5 (e.g., empyema, pleural fluid, sinus aspirate, middle ear), from respiratory specimens and blood in 4 patients, and from respiratory and other usually sterile sites in 3 patients.
The baseline demographic characteristics of the cases and controls are shown in When the analysis was restricted to cases with S. pneumoniae recovered from blood or another usually sterile site and their matched controls, similar results were found. There were significant differences between cases and controls in baseline CD4 cell counts (P = .015), CD4 cell counts at diagnosis (P = .008), history of pneumonia (P = .01), history of P. carinii pneumonia (P = .05), stage of disease at diagnosis (p = .007), hematocrit at baseline and at diagnosis (P = .004 and .003, respectively), albumin at baseline and at diagnosis (P = .005 and .007, respectively), creatinine at diagnosis (P = .02), and use of zidovudine (P = .04). Black race was not associated with being a case (P = .76).
Our multivariate analysis of factors associated with pneumococcal infection for all cases and controls is shown in table 4. African Americans among cases than controls (85% vs. 69%, P = .01). Seventy-one percent of cases and 75% of controls were male. Sixty-nine percent of cases were current smokers as were 67% of controls. Injection drug use was the most common risk behavior for HIV transmission in cases and controls but was not associated with being a case or with pneumococcal pneumonia.
As shown in table 2, cases were less likely than controls to have symptomatic HIV disease (e.g., thrush, fever, weight loss) at baseline (21% vs. 47%) and were more likely to have a diagnosis ofAIDS (48% vs.21 %, P = .001). The mean baseline CD4 lymphocyte count was significantly lower in cases than controls (187 vs. 346 cells/mm 3 , P = .001), as were the mean hematocrit (34.0% vs. 38.4%, P = .001) and serum albumin levels (3.7 vs. 4.2 g/dL, P = .001). Table 3 shows that at the index time, 66% of the cases had AIDS compared with 34% of controls (P = .001). In only 1 case was an AIDS diagnosis based on recurrent bacterial pneumonia. Mean CD4 cell count (194 vs. 249 cells/mm 3 , P = .01), hematocrit (29.8% vs. 35.6%, P =.0001), and albumin (3.2 vs. 3.9 g/dL, P = .001) were all significantly lower in cases than controls. Serum creatinine was significantly higher in cases than controls (1.8 vs. 1.1 mg/dL, P = .002). Cases were more likely than controls to have had a previous bacterial (P = .001) or P. carinii pneumonia (P = .02).
Cases were less likely to be receiving zidovudine than were controls (P = .04) at the index time. There was no significant difference between cases and controls in use of trimethoprimsulfamethoxazole (11 % vs. 17%). Overall, there was no significant difference between cases and controls in receipt of the pneumococcal vaccine (41% vs. 37%). However, when stratified by CD4 cell level within 90 days of vaccine administration, use of vaccine was associated with a decreased risk of 
Discussion
Our study was designed to determine which factors are associated with pneumococcal infections in HIV-infected subjects. Advanced HIV infection (:::;200 CD4 cells/mm 3 ) and past history of pneumonia were important predictors of disease. In other studies, the incidence of bacterial pneumonia also was higher in advanced HIV disease [8] [9] [10] . Because our controls could not have had a prior history of unspecified bacterial pneumonia, our results may have been biased with respect to this risk factor. A low albumin level was significantly associated with pneumococcal infections in our multivariate analysis, suggesting that poor nutritional status is a risk factor for pneumococcal disease independent of advanced immunosuppression. We also demonstrated an association between African American race and pneumococcal disease.
Because S. pneumoniae can be recovered from nonsterile sites in patients without disease, using only cases with infection at a usually sterile site improves diagnostic specificity. Such an approach discards many patients with pneumococcal pneumonia, however, because the majority ofpatients with pneumococcal disease do not have dissemination to sterile sites. Use of a strict case definition of nonsterile sites (mostly respiratory) can yield valuable data while retaining specificity. Our analysis of the 36 cases with pneumococcal infection of a normally sterile site confirmed most ofthe findings ofour overall sample, with the notable exception of increased risk for African American race. The lack of association between race and invasive pneumococcal disease could be a result of the smaller sample size or may suggest an increased risk of pneumococcal respiratory infections but not bacteremia in African Americans with HIV infection. In a previous study, the incidence of pneumococcal bacteremia was 2.5-fold higher in HIV-seronegative African Americans than in whites residing in Charleston County, South Carolina [2] . The reason that African Americans are at increased risk for pneumococcal disease is not known.
The use of pneumococcal vaccine in HIV-infected patients, although recommended by the ACIP, has been debated among medical professionals [13 -15] . Numerous vaccine failures have been reported [13 -15] , and no clear guidelines as to which patients benefit the most from the vaccine have been established. Our data suggest the pneumococcal vaccine has a protective effect in patients with >200 CD4 cells/mm 3 at vaccination. No protection was seen for patients with~200 CD4 cells/mm 3 at vaccination. This is consistent with the finding of progressive B lymphocyte dysfunction in advanced HIV disease and loss of response to neoantigens [26] . Steinhoff et al. [27] showed that a T cell-dependent, protein-conjugated polysaccharide vaccine was more immunogenic than a pure polysaccharide vaccine (Haemophilus influenza type b) in HIVinfected men, but in patients with advanced disease, neither preparation was particularly immunogenic. Janoff et al. [28] showed that antibody responses to pneumococcal polysaccharide vaccine were less pronounced in AIDS patients than in asymptomatic HIV-seropositive patients. Huang et al. [29] also reported that antibody responses to pneumococcal polysaccharides were more pronounced in patients with higher levels of CD4 cells.
Our data suggest that the reduced immunogenicity of pneumococcal vaccine in patients with low CD4 cell counts is associated with a lack of protection against disease. Although such patients were more likely to have been vaccinated than were similar controls, we do not believe that pneumococcal vaccine increases the risk of disease in such patients. Because our sample size was small, we cannot conclude that pneumococcal vaccine has no value in patients with low CD4 cell counts. In addition, exclusion of controls with a history of bacterial pneumonia, which may have,prompted administration ofpneumococcal vaccination by their physicians, could bias our study against finding a protective .effect in patients with advanced HIV disease. Nonetheless, the data on the immunogenicity of polysaccharide vaccines in advanced HIV infection suggest that any benefit is likely to be limited. These findings underscore the need for more immunogenic polysaccharide vaccines, such as protein-conjugated preparations.
The use of zidovudine was also associated with a lower risk of pneumococcal disease. It was suggested previously that use of zidovudine would boost the response to pneumococcal vaccine by augmenting the production of antibody in patients with low CD4 cell counts [30] . We found that zidovudine use at the index time was protective, independent of vaccination. This may be the result of zidovudine-associated improvements in both cellular and humoral immunity. Prophylactic use of trimethoprim-sulfamethoxazole for P. carinii pneumonia, however, was not associated with a protective effect against S. pneumoniae. Possible reasons for the lack of association in-clude patients' nonadherence with trimethoprim-sulfamethoxazole prophylaxis regimens (resulting in inadequate serum levels to protect against pneumococcal disease), strains of pneumococcus that are not sensitive to trimethoprim-sulfamethoxazole, or inadequate doses of the drug to prevent pneumococcal disease when used for P. carinii prophylaxis. Recent evidence shows that colonization with trimethoprim-sulfamethoxazoleresistant pneumococci is significantly more common in AIDS patients using this agent for prophylaxis than in HIV-seropositive patients with higher CD4 cell counts [31] .
Unlike previous investigators [32] [33] [34] , we did not find an association between pneumococcal disease and injection drug use at baseline. Hoge et al. [35] showed that during an outbreak of pneumococcal pneumonia among incarcerated subjects, injection drug use was a risk factor independent of HIV status. We were unable to quantify the frequency of injection drug use in our patients. Endocarditis was weakly associated with pneumococcal disease in our study, however, suggesting that ongoing and active injection drug use may be a risk factor. We did not find an association between pneumococcal disease and incarceration or residence in a shelter as others have found [2, 35] . Epidemic pneumococcal disease is unusual, however, and our power to detect outbreaks was limited. We also did not detect an association between cigarette smoking at baseline and pneumococcal infections. A large proportion of cases and controls smoked, but data on current smoking practices were not available for most subjects at the index time. A recent study clearly demonstrated an association between current cigarette smoking and bacterial pneumonia in patients with HIV infection [10] .
Case-control studies are subject to several potential biases. The nested design of our study ensured that we identified all cases of pneumococcal disease that occurred in our cohort. There was no recall bias since cases were identified using reports by our institution's microbiology laboratory of all positive pneumococcal cultures during the study period, and we used patients who had complete medical records. Identical methods were used to abstract all data for cases and controls, regardless of case-control status. The controls were selected randomly from the same cohort of subjects by use of a systematicalgorithm. Controls were confirmed as having no evidence of unspecified bacterial pneumonia at any time during followup. Finally, controls were matched to cases by date of first presentation to the clinic to minimize bias that might result from temporal trends in the treatment of HIV disease. They were further matched by follow-up time to ensure similar opportunity to receive vaccine and drug therapy. By use of conditionallogistic regression, we were able to adjust for confounding variables in our assessment of risk factors.
In summary, we found several important risk factors for the development of pneumococcal disease in HIV-positive patients: African American race, advanced stage ofHIV infection, and past history of pneumonia. Zidovudine use appeared to be protective against pneumococcal disease. Pneumococcal polysaccharide vaccine was associated with a decreased risk of pneumococcal disease if administered when subjects had 200 CD4 cells/mm 3
• These finding underscore the importance of early diagnosis of HIV infection and administration of pneumococcal vaccine before advanced immunodeficiency develops.
